GSK’s FluLaval Approval Raises Estimated Influenza Vaccine Doses To 115 Mil.
This article was originally published in The Pink Sheet Daily
FluLaval is approved by FDA for immunization of adults against influenza Oct. 5.
You may also be interested in...
Results from one of two Phase I pandemic flu vaccine trials in the third quarter will support accelerated European regulatory efforts.
GSK submits a BLA for FluLaval, acquired as part of its 2005 purchase of ID Biomedical, to FDA March 23.
GlaxoSmithKline plans to acquire ID Biomedical for $1.4 bil., a deal that could provide GSK with a second flu vaccine in the U.S. for the 2006/2007 flu season.